Newsroom

September 2015

• Press release Sep 30, 2015

  Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis

  In the FUTURE 1 study, secukinumab showed rapid and significant efficacy in active psoriatic arthritis (PsA) patients, including improvement of skin and joint disease and reduction in progression of…
• 
  Story Sep 29, 2015 Patient Perspectives

  Heart failure: coping with one of the world’s biggest killers

  Patients are learning to live with a chronic disease that will affect one in 5 people over age 40.

• Press release Sep 28, 2015

  Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist®

  Phase III data showed median overall survival of 25.6 months in patients with BRAF+ V600E/K metastatic melanoma who received Tafinlar + Mekinist Tafinlar + Mekinist combination also demonstrated…
• Press release Sep 27, 2015

  Novartis drug Afinitor® significantly improves progression-free survival in advanced nonfunctional gastrointestinal and lung NET

  In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional…
• Press release Sep 25, 2015

  Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval

  Positive opinion from EU review body puts Entresto on track to be approved for HFrEF patients across Europe likely by year end Entresto was studied in world's largest heart failure trial which…
• Press release Sep 24, 2015

  Novartis appoints James E. Bradner, MD as President of the Novartis Institutes for BioMedical Research as Mark Fishman retires

  New leader to continue to drive long-term innovation in Novartis research in wide range of therapeutic areas Basel, September 24, 2015 - Novartis announced today that Dr. James (Jay) E.…
• Press release Sep 24, 2015

  Novartis nomme le Dr James E. Bradner Président des Instituts Novartis pour la Recherche Biomédicale suite au prochain départ à la retraite de Mark Fishman

  Un nouveau responsable pour continuer de stimuler l'innovation à long terme au sein de la recherche chez Novartis dans des domaines thérapeutiques très variés Bâle, le 24 septembre 2015 -…
• Press release Sep 24, 2015

  Novartis ernennt Dr. James E. Bradner zum Präsidenten der Novartis Institutes for BioMedical Research, da Mark Fishman in den Ruhestand tritt

  Neuer Leiter wird weiterhin langfristige Innovationen in zahlreichen Therapiegebieten der Novartis Forschung vorantreiben Basel, 24. September 2015 - Novartis gab heute bekannt, dass…
• Press release Sep 24, 2015

  Novartis lance « Novartis Access », une gamme de médicaments à prix abordables pour lutter contre les maladies chroniques dans les pays à faible revenu

  Une approche unique en son genre dans l'industrie de la santé, qui vise à rendre 15 médicaments plus facilement disponibles et plus accessibles pour traiter les maladies cardiovasculaires, le diabète…
• Press release Sep 24, 2015

  Novartis lanciert "Novartis Access", ein Portfolio von erschwinglichen Medikamenten zur Behandlung von chronischen Erkrankungen in Ländern mit niedrigen Einkommen

  Neuartiger Portfolioansatz in der Gesundheitsbranche mit dem Ziel, die Verfügbarkeit und Erschwinglichkeit von 15 Medikamenten gegen Herz-Kreislauf-Erkrankungen, Diabetes, Atemwegserkrankungen und…
• Press release Sep 24, 2015

  Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries

  First-of-its-kind portfolio approach in healthcare industry, aiming to increase availability and affordability of 15 medicines against cardiovascular diseases, diabetes, respiratory illnesses and…
• 
  Story Sep 22, 2015 From Our Labs

  Stopping free radicals at their source

  Compounds that block the production of damaging molecules might shed light on their role in disease—and lead to new therapies.